40 results about "Flavivirus" patented technology

This invention discloses the application of the DNAL1 gene as a target in screening drugs for the prevention and treatment of Zika virus or dengue virus type 2 infection, specifically the application of screening drugs for the prevention and / or treatment of Zika virus or dengue virus type 2 infection with the aim of inhibiting or knocking out the DNAL1 gene. The invention has found that the DNAL1 gene is a key host factor promoting the replication of Zika virus or dengue virus type 2, and that inhibiting the DNAL1 gene through siRNA or knocking out the DNAL1 gene through CRISPR / Cas9 can inhibit the replication of Zika virus or dengue virus type 2. The DNAL1 gene is a potential host factor for flaviviruses, and this invention provides a potential target for the prevention and / or treatment of Zika virus or dengue virus type 2 infection.

The invention discloses establishment and application of a flavivirus replication-dependent RNA (Ribonucleic Acid) recombination experiment system, and belongs to the technical field of biology. The RNA recombination system comprises two components: a tembusu virus E gene deleted subgenome replicon CQW1-delta E, and a defective virus genome CQW1-delta NS1 or MM1775-delta NS1 with a part of NS1 gene sequence deleted. The two components cannot generate progeny viruses independently, but after the two components are co-transfected, a large number of recombinant progeny viruses can be generated within several days after transfection due to RNA recombination, the recombination efficiency is extremely high, continuous passage is not needed, the construction period is greatly shortened, and the production cost is saved; meanwhile, the generated progeny virus can form plaques on cells, and by means of plaque counting, the method can be applied to quantitative measurement of the RNA recombination efficiency and analysis of key factors influencing the tembusu virus RNA recombination.

The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.

The present invention includes composition and methods for making multivalent vaccines for immunization against Flavivirus and / or arboviruses including a multivalent Virus Like Particles (VLP) and mixtures thereof, the method comprising: method of making a Flavivirus and / or arboviruses Virus Like Particles (VLP) comprising: inserting two or more nucleic acids that encode at least one Flavivirus protein into a lentiviral backbone vector; generating a lentivirus by transfecting a first cell line with the lentiviral backbone vector and isolating the lentivirus therefrom; transducing a second cell line with the lentivirus; culturing the transduced cell line under conditions in which the multivalent Flavivirus Virus Like Particles (VLP) are released from the cell line; and isolating the Flavivirus Virus Like Particles (VLP) from a culture supernatant, wherein a cell line makes a virus-specific VLP, and the VLPs are purified and then mixed in different combinations to make the multivalent vaccine.

The application discloses a kind of establishment and application of flavivirus replication-dependent RNA recombination experimental system, belong to the field of biotechnology.The RNA recombination system includes two components: tanbusu virus E gene deletion subgenomic replicon CQW1-ΔE, and the defective virus genome CQW1-ΔNS1 or MM1775-ΔNS1 missing partial NS1 gene sequence.The two components cannot produce progeny virus alone, but after co-transfection, due to RNA recombination, a large number of recombinant progeny viruses can be produced within a few days after transfection, the recombination efficiency is extremely high, and continuous passage is not required, greatly shortening the construction cycle and saving production costs;At the same time, the progeny virus can form plaques on cells, and the efficiency of RNA recombination can be quantitatively measured by plaque counting, and the key factors affecting tanbusu virus RNA recombination can be analyzed.

Ligands that target Flavivirus; conjugates comprising radicals of such ligands; compositions comprising the conjugates; methods of use of the ligands and / or conjugates to target active agents to the Flavivirus E protein; and methods of use of the conjugates to treat and prevent Flavivirus infection.

The invention belongs to the technical field of microbial viruses, and particularly relates to a culture method for improving the virus titer of duck flavivirus, which comprises the following steps: step 1, preparing a culture solution, accurately weighing RPMI1640 dry powder, dissolving the RPMI1640 dry powder in three-distilled water, then adding a proper amount of fetal calf serum and double antibodies, filtering and sterilizing, then sub-packaging into sterile culture bottles, and preparing the culture solution for later use; storing at a proper temperature for later use; 2, preparing cells, selecting suitable cells, inoculating the cells into a culture flask, and carrying out single-layer culture by using an RPMI1640 culture solution to ensure that the cells are in a good growth state before the cells are inoculated with viruses, The method has the beneficial effects that by selecting a suitable host cell line, the cells are ensured to be in a healthy state, the performance reduction caused by high algebraic culture is avoided, and the cell quality is improved. In addition, the cell culture medium suitable for virus production is selected, and the culture medium with high transfection efficiency and cell maintaining capacity after transfection can remarkably improve the virus titer.

This disclosure relates to stabilizers for compositions comprising live-attenuated flaviviruses, methods for stabilizing live-attenuated flaviviruses, and stabilized live-attenuated flavivirus vaccine compositions.

The present invention pertains to compounds that inhibit Flavivirus NS2B-NS3 proteases and are potent and selective inhibitors of the West Nile virus and Zika virus. The compounds of the invention can be used alone or in combination with other agents to treat infections caused by these viruses. Additionally, the invention relates to pharmaceutical compositions containing these compounds.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The present invention relates to the field of biopharmaceutical technology, and more specifically, to a novel use of eltrombopag. Eltrombopag can act on the NS2B / NS3pro target site, inhibiting the activity of NS2B / NS3pro, while also inhibiting the activity of dengue and Zika viruses. It can also be used to inhibit the activity of flaviviruses and has therapeutic effects on diseases mediated by them.

Ligands that target Flavivirus; conjugates comprising radicals of such ligands; compositions comprising the conjugates; methods of use of the ligands and / or conjugates to target active agents to the Flavivirus E protein; and methods of use of the conjugates to treat and prevent Flavivirus infection.

The invention relates to the technical field of plant virus detection, in particular to a pepper vein flavivirus detection method and system based on RT-RAA-CRISPR / Cas12a and application of the pepper vein flavivirus detection method and system. The invention discloses a pepper vein flavivirus detection method based on RT-RAA-CRISPR / Cas12a. The pepper vein flavivirus detection method comprises the following steps: S1, extracting virus RNA (Ribonucleic Acid) from a plant leaf to be detected; s2, adding RNA (Ribonucleic Acid) of a sample to be detected into the RT-RAA amplification system, and carrying out isothermal amplification at 37-42 DEG C for 10-30 minutes to obtain an RT-RAA amplification product; s3, adding the RT-RAA amplification product into a CRISPR / Cas12a (clustered regularly interspaced short palindromic repeats / CRISPR associated 12a) detection system, and reacting for 20 to 30 minutes under the condition of 37 DEG C; s4, detecting fluorescence change in real time, and judging a result through a fluorescence signal; if a fluorescence signal is detected, it is indicated that the pepper vein flavivirus exists in the RNA of the to-be-detected sample, efficient amplification is achieved through a recombinase-single-chain binding protein-primer compound, and high sensitivity and specificity of detection are ensured through accurate nucleic acid recognition and signal amplification functions; the method is especially suitable for rapid screening and diagnosis of plant viruses in limited resource environments such as fields.

The invention relates to the field of enzyme engineering and molecular biology, and discloses a heterologous virus-derived chimeric multifunctional 5 '-'capping' enzyme, and the mRNA vaccine 5 '-'capping' enzyme is formed by sequentially connecting an RNA triphosphatase functional domain derived from rabbit fibroma virus, a guanylyl transferase functional domain and a methyltransferase functional domain derived from flavivirus NS5 protein. According to the invention, RNA triphosphatase, guanylyl transferase and a methyltransferase structural domain with a dual methylation function are integrated into a single polypeptide chain, so that a catalytic process of completing synthesis of a 5'cap 'structure of the mRNA vaccine by one enzyme and one step is realized, the modification process flow of the mRNA vaccine is remarkably simplified, and the consistency and reproducibility of mRNA vaccine production are improved.

A computer-implemented method of determining infectivity of a flavivirus-containing sample is described. The method includes receiving (S1), with a computing device (10), image data indicative of an image of at least a part of a container (50, 50a, 50b) comprising a composition containing host cells with one or more foci (51) generated by infecting the host cells with the flavivirus over an incubation period and optionally subsequent staining of the incubated host cells. The method further includes determining (S2) a number of foci (51) in the at least part of the container (50, 50a, 50b) based on processing the received image data with at least one trained deep learning algorithm of the computing device (10), wherein the number of foci (51) is indicative of the infectivity of the flavivirus in the sample.

The present invention relates to a method for the early detection, monitoring and prognosis of flavivirus-induced infections, comprising detecting complexes formed in biological samples by the flavivirus nonstructural glycoprotein NS1 and plasma lipoprotein particles during the clinical phase of infection.

To provide vaccine compositions capable of increasing an immune response against a flavivirus, such as Zika virus, in a mammal (e.g., a human), and to provide methods of increasing the immune response.SOLUTION: This document provides methods and materials related to selected Zika virus polypeptides. For example, vaccine compositions are provided that contain one or more selected Zika virus polypeptides provided herein and have the ability to increase an immune response against a flavivirus, such as Zika virus, in a mammal (e.g., a human).SELECTED DRAWING: None

The invention discloses an aromatic ether modified ginsenoside Rb1 derivative or a pharmaceutically acceptable salt thereof, wherein the structural formula of the aromatic ether modified ginsenoside Rb1 derivative is shown in the specification. According to the compound, high-selectivity etherification modification is carried out on a ginsenoside Rb1 sugar ring, an aromatic pharmacophore is introduced, the inhibitory activity on Zika virus and dengue virus is remarkably improved, and the compound has excellent metabolic stability and low cytotoxicity; the preparation method is realized through one-step reaction, is mild in condition and good in yield, and has an industrial production prospect; the derivative disclosed by the invention can be used for preparing medicines for resisting Zika virus and dengue virus, and dosage forms comprise tablets, injections and the like; .

The invention features modified alphavirus or flavivirus virus-like particles (VLPs). The invention provides methods, compositions, and kits featuring the modified VLPs. The invention also features methods for enhancing production of modified VLPs for use in the prevention or treatment of alphavirus and flavivirus-mediated diseases. The invention also provides methods for delivering agents to a cell using the modified VLPs.

This invention discloses the application of host ITCH as a drug target in the preparation of drugs against normal flavivirus infection, belonging to the field of biomedical technology. This invention is the first to propose and verify the host E3 ubiquitin ligase ITCH as a key target for anti-normal flavivirus infection, and provides an antiviral strategy based on interfering with the interaction between host ITCH and normal flavivirus capsid proteins or inhibiting the expression level / ubiquitin ligase activity of host ITCH. Unlike existing mainstream viral target strategies, this invention is a novel antiviral approach based on host factors, providing a new target and theoretical basis for developing broad-spectrum, low-drug-resistance anti-normal flavivirus drugs.

The present invention relates to specific compounds for use in the prevention or treatment of viral infections caused by RNA viruses.

The present invention relates to an antiviral composition comprising a microalga extract as an active ingredient. More specifically, a Tetraselmis extract effectively inhibits the proliferation and replication of flaviviruses and thus can be advantageously used as an antiviral agent, a pharmaceutical composition, a health functional food composition, or a quasi-drug composition for anti-flavivirus activity.

Compounds, methods, and compositions for treating or preventing viral infections using nucleoside compounds. The nucleoside compounds have increased antiviral activity potential with the result of inhibiting at least one of flaviviruses, herpesviruses, polyomaviruses, alphaviruses, enteroviruses, filoviruses matonaviruses, phenuiviruses, Hepatitis B virus, and / or coronaviruses.

This disclosure relates to engineered flavivirus envelope (E) peptides containing stem-transmembrane domain mutations, virus-like particles (VLPs) containing said engineered E peptides, and the use of said E peptides in the treatment and prevention of flavivirus infection.

The invention relates to application of Liushen pills in treating diseases caused by various virus infections. The inventor finds that the Liushen pill has a good inhibition effect on various viruses, especially Coxsackie virus A type 9, respiratory syncytial virus, adenovirus C type 5, vaccinia virus, fever with thrombocytopenia syndrome bunyavirus, porcine epidemic diarrhea virus, pangolin coronavirus, Zika virus and Japanese encephalitis virus. In view of the strong inhibition effect on various viruses such as poxvirus, enterovirus, respiratory syncytial virus, adenovirus, bunyavirus, coronavirus and flavivirus observed by the Liushen pill, the Liushen pill is likely to become a specific medicine for diseases caused by infection of various viruses.

The present invention provides polypeptides, and polypeptide dimers, comprising a modified flavivirus envelope E polypeptide, wherein the modified flavivirus envelope E polypeptide comprises i) a cysteine residue in a fusion loop epitope of ectodomain DII; and ii) a cysteine residue in ectodomain DI located in an N-terminal portion of the polypeptide, nucleic acids, vectors, host cells, and pharmaceutical compositions comprising the same, and methods of inducing an immune response in subjects by administering the pharmaceutical compositions of the invention.

Provided is a flavivirus cross neutralizing antibody which has an excellent ability to control infection with suppressed ADE. This is a flavivirus cross neutralizing antibody that specifically binds to domains of E protein of flavivirus and thereby has an ability to control infection with at least two viruses included in the flavivirus. The domains of E protein include a plurality of domains including domain III. The flavivirus includes, for example, Zika virus, dengue virus types 1-4, and Japanese encephalitis virus.